Recently, dual targeting of HIF-1α and AR pathways by HIF-1α inhibitors and enzalutamide, a second generation AR inhibitor, showed synergistic effect in castration-resistant prostate cancer cell lines, also resulting in decreased VEGF-A levels [81]. Here, AR is linked to prostate cancer.